{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:23Z","timestamp":1791521423841,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase (CDK) 4\/6 inhibitors with endocrine therapy are standard of care for hormone receptor (HR)-positive, HER2-negative breast cancer in metastatic and adjuvant settings. The ribociclib label lists dry eye and increased lacrimation among ocular reactions in under 10% of patients, and isolated vortex keratopathy, epithelial keratopathy, and palinopsia are described. To our knowledge, neither neurotrophic keratitis (NK) nor management of an ocular adverse event with amniotic membrane transplantation (AMT) has been reported with any CDK4\/6 inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 42-year-old premenopausal woman with stage IIB (cT2N1) HR-positive\/HER2-negative invasive ductal carcinoma achieved a pathologic complete response after neoadjuvant chemotherapy and bilateral mastectomy. Adjuvant abemaciclib was discontinued after one month for refractory gastrointestinal toxicity, without ocular complaints. Ribociclib 400 mg\/day was initiated. After approximately four months she developed bilateral blurred vision; optometry identified bilateral inferior superficial punctate keratitis (SPK), and preservative-free lubrication was started. At the fifth-month visit, bilaterally reduced corneal sensitivity, a feature of early neurotrophic keratopathy, was documented, and prednisolone acetate 1% was begun. With symptoms failing to improve, ribociclib was held. At the six-month visit, with central SPK, tear-film instability, and further visual decline despite corticosteroid, amniotic membrane grafts with bandage contact lenses were placed sequentially in each eye, and topical cyclosporine 0.05% was started. Ribociclib was permanently discontinued. Right-eye vision normalized within five months; the left eye recovered over fifteen months. Anastrozole and all other concomitant medications were continued without recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this appears to be the first reported case of bilateral neurotrophic keratitis during CDK4\/6 inhibitor therapy and the first ribociclib-associated ocular adverse event refractory to standard topical therapy that improved after procedural intervention. A Naranjo score of 5 indicates a probable association, supported by a documented normal ocular baseline on the same concomitant medications, absence of ocular toxicity during brief prior abemaciclib exposure, and improvement after dechallenge with continued anastrozole. As a single, signal-generating case, causality cannot be established; additional reports and pharmacovigilance analyses are needed. As adjuvant use expands, clinicians should watch for corneal nerve toxicity beyond dry eye, ask routinely about visual symptoms, and refer early for eye care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1932226","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:25:54Z","timestamp":1791519954000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Ribociclib-associated bilateral neurotrophic keratitis requiring amniotic membrane transplantation during adjuvant treatment of early breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Danielle","family":"DeCicco","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, West Virginia University Cancer Institute","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Nethagani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West Virginia University Cancer Institute","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingo","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, West Virginia Eye Institute","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Safi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West Virginia University Cancer Institute","place":["Morgantown, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","volume-title":"KISQALI (ribociclib) [Prescribing information]","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.4.7","article-title":"Schwann cells are key regulators of corneal epithelial renewal","volume":"64","author":"Mirmoeini","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1668446","article-title":"Ocular toxicity events of cyclin-dependent kinase 4\/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221101799","article-title":"Vortex keratopathy associated with ribociclib","volume":"29","author":"T\u00fcrkel","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2019.11.003","article-title":"Ribociclib-associated vortex keratopathy","volume":"55","author":"Saeed","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12886-025-04043-6","article-title":"CDK4\/6 inhibitor-associated vortex keratopathy: a case report","volume":"25","author":"Shu","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241301406","article-title":"Bilateral epithelial keratopathy and punctate keratitis due to ribociclib","volume":"31","author":"Bilen","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1430341","article-title":"Palinopsia associated with the CDK4\/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports","volume":"14","author":"Martos","year":"2024","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2045035","article-title":"Neurotrophic keratopathy: current challenges and future prospects","volume":"54","author":"NaPier","year":"2022","journal-title":"Ann Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.04.003","article-title":"Neurotrophic keratopathy","volume":"66","author":"Dua","year":"2018","journal-title":"Prog Retinal Eye Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"CD015723","DOI":"10.1002\/14651858.CD015723.pub2","article-title":"Medical and surgical interventions for neurotrophic keratopathy","volume":"2025","author":"Kruoch","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","volume":"393","author":"Gray","year":"2019","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"JCO"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(26)00064-1","article-title":"Lymph node surgery and CDK4\/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials","volume":"27","author":"Pfob","year":"2026","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2012.02865.x","article-title":"Dry eye syndrome in aromatase inhibitor users","volume":"41","author":"Turaka","year":"2013","journal-title":"Clin Exper Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTO.S355091","article-title":"A review of ocular complications associated with medications used for anxiety, depression, and stress","volume":"14","author":"Constable","year":"2022","journal-title":"OPTO"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2385497","article-title":"Eye disorders associated with selective serotonin reuptake inhibitors: a real-world disproportionality analysis of FDA adverse event reporting system","volume":"24","author":"Li","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2025.17.6.692","article-title":"Efficacy of a combination therapy of montelukast and antihistamines in allergic rhinitis: a systematic review and network meta-analysis","volume":"17","author":"Kim","year":"2025","journal-title":"Allergy Asthma Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80217-5","article-title":"Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models","volume":"25","author":"Spangler","year":"2003","journal-title":"Clin Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0083-1","article-title":"Comparison of three methods (An updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference","volume":"36","author":"Th\u00e9ophile","year":"2013","journal-title":"Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2007.11.005","article-title":"Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4)","volume":"37","author":"Atanasoski","year":"2008","journal-title":"Mol Cell Neurosci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000370324","article-title":"The role of Schwann cell-axon interaction in peripheral nerve regeneration","volume":"200","author":"Namgung","year":"2014","journal-title":"Cells Tissues Organs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105952","article-title":"Schwann cell functions in peripheral nerve development and repair","volume":"176","author":"Bosch-Queralt","year":"2023","journal-title":"Neurobiol Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1603752","article-title":"Pharmacologically targeting Schwann cells to improve regeneration following nerve damage","volume":"13","author":"Alhamdi","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0695-8","article-title":"Lysosomal trapping of palbociclib and its functional implications","volume":"38","author":"Llanos","year":"2019","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2026.06.020","article-title":"Corneal epithelial alterations associated with cyclin-dependent kinase 4\/6 inhibitor therapy in hormone receptor\u2013positive breast cancer","volume":"290","author":"Ozbay","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"B32","unstructured":"New York, NY\n          Pfizer\n          IBRANCE (palbociclib)[Prescribing information]\n          \n          2026"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1186\/s12889-026-27025-9","article-title":"Comprehensive effects and dose-response relationship of screen exposure on university students\u2019 physical and mental health and academic performance in the digital age: a systematic review and meta-analysis","volume":"26","author":"Zeng","year":"2026","journal-title":"BMC Public Health"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diamond.2025.112001","article-title":"Voltammetric detection of ribociclib in cancer therapy using glassy carbon electrode and boron-doped diamond electrode","volume":"152","author":"Aslan","year":"2025","journal-title":"Diamond Relat Mater"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.113933","article-title":"Identification and structural characterization of potential degraded impurities of ribociclib by time of flight -tandem mass spectrometry, and their toxicity prediction","volume":"197","author":"Sahu","year":"2021","journal-title":"J Pharm BioMed Anal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpba.2019.01.017","article-title":"Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry","volume":"166","author":"Bao","year":"2019","journal-title":"J Pharm BioMed Anal"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2024.111580","article-title":"First voltammetric studies, spectrophotometric and molecular docking investigations of the interaction of an anticancer drug ribociclib-DNA and analytical applications of disposable pencil graphite sensor","volume":"206","author":"Aslan","year":"2024","journal-title":"Microchem J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1932226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:25:55Z","timestamp":1791519955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1932226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1932226"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1932226","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1932226"}}